Rosenthal L Lily, Spickermann Tabea Katharina, Ulrich Sarah Marie, Dalla Pozza Robert, Netz Heinrich, Haas Nikolaus A, Schramm René, Schmoeckel Michael, Hagl Christian, Hörer Jürgen, Michel Sebastian, Grinninger Carola
Department of Heart Surgery/Division for Pediatric and Congenital Heart Surgery, Ludwig Maximilian University Munich, Munich, Germany.
European Pediatric Heart Center Munich (EKHZ), Munich, Germany.
Front Transplant. 2024 Oct 10;3:1452617. doi: 10.3389/frtra.2024.1452617. eCollection 2024.
The aim of this study was to analyze the results after pediatric heart transplantation (pHTx) at our single center differentiating between ABO-incompatible (ABOi) and -compatible (ABOc) procedures.
We retrospectively analyzed outcomes of ABO-incompatible HTx procedures performed at our center and compared the data to ABO-compatible HTx of the same era. Eighteen children (<17 months) underwent pediatric HTx and seven of them underwent ABO-incompatible HTx between 2003 and 2015.
Mechanical circulatory support as bridge to transplant was necessary in 3/7 patients before ABO-incompatible HTx and in 3/11 patients before ABO-compatible HTx. Mean waiting time on the list was 36 ± 30 days for ABO-incompatible HTx and 86 ± 65 days for ABO-compatible HTx. The 5-years re-transplant free survival was 86% following ABO-incompatible and 91% after ABO-compatible. In the cohort undergoing ABO-incompatible HTx, 2 patients showed an acute cellular rejection, while early graft failure was not observed. In the cohort undergoing ABOcompatible HTx, acute cellular rejection was observed in 9/11 patients, with early graft failure occurring in nine and CVP in two. A total of ten children were listed for ABO-incompatible HTx after 2015; however, all ten underwent an ABO-compatible transplantation.
This study adds much needed information to the literature on ABOi-HTx by showing with a retrospective single center analysis that it is safe and leads to shorter waiting times. We conclude that strategies for ABOi-HTx should be elaborated further, potentially allowing more timely transplantation and thereby preventing waiting list complications such as the need for mechanical circulatory support and even death.
本研究旨在分析我院单中心小儿心脏移植(pHTx)术后结果,区分ABO血型不相容(ABOi)和相容(ABOc)手术。
我们回顾性分析了我院进行的ABO血型不相容心脏移植手术的结果,并将数据与同一时期的ABO血型相容心脏移植进行比较。2003年至2015年间,18名儿童(<17个月)接受了小儿心脏移植,其中7名接受了ABO血型不相容心脏移植。
3/7例ABO血型不相容心脏移植患者和3/11例ABO血型相容心脏移植患者术前需要机械循环支持作为移植桥梁。ABO血型不相容心脏移植患者的平均等待时间为36±30天,ABO血型相容心脏移植患者为86±65天。ABO血型不相容心脏移植术后5年无再次移植生存率为86%,ABO血型相容心脏移植术后为91%。在接受ABO血型不相容心脏移植的队列中,2例出现急性细胞排斥反应,未观察到早期移植物功能衰竭。在接受ABO血型相容心脏移植的队列中,9/11例患者出现急性细胞排斥反应,9例发生早期移植物功能衰竭,2例发生中心静脉压升高。2015年后共有10名儿童被列入ABO血型不相容心脏移植名单;然而,这10名儿童均接受了ABO血型相容移植。
本研究通过回顾性单中心分析表明ABOi-HTx安全且等待时间较短,为ABOi-HTx文献增添了急需的信息。我们得出结论,应进一步完善ABOi-HTx策略,可能允许更及时的移植,从而预防等待名单并发症,如需要机械循环支持甚至死亡。